Gandhar Oil Refinery says USFDA closed inspection on co’s Taloja facility – CNBC TV18

Gandhar Oil Refinery Ltd. announced on Wednesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its manufacturing facility in Taloja.

“The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded the inspection is “closed” under 21 CFR 20.64 (d)(3),” the company said in a statement.

This classification by the USFDA suggests that while the Taloja facility met most of the regulatory standards, the agency found minor issues that may be addressed through voluntary actions by the company. The inspection’s closure under VAI typically does not result in penalties or the need for formal regulatory actions.

The inspection of the Taloja plant, a key manufacturing site for the company, was part of routine regulatory oversight, ensuring compliance with global standards for pharmaceutical-grade oils and other products. The company has not provided further details on the specific areas identified for voluntary action.

Registered in 2013, Gandhar Oil Refinery supplies & trades petroleum products, transformer oil, mineral oil etc. The supplier company is located in Taloja, Maharashtra.

Shares of Gandhar Oil Refinery had closed prior to the announcement, up 0.4% at ₹225 on Wednesday.

Also Read : Nifty 50 at three-week low, Sensex drops 500 points as heavyweights continue to drag